Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Delivering mitochondrial health
      • Orphan Drugs
    • Relevant publications
  • Mitochondrial Disease
    • Primary mitochondrial disease
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
  • AGM 2025
  • Contact
    • Privacy policy

Press releases

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
1 February, 2023

Abliva Appoints Dag Nesse as Vice President of Clinical Operations

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the appointment of Dag Nesse as V ...
Continue reading
20 January, 2021
Regulatory

Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the Board ...
Continue reading
7 November, 2017
Regulatory

NeuroVive Board Chair Resigns, New Chair Elected

Lund, Sweden, 7 November 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that Gregory Batcheller resigned as Chair of the NeuroVive Pharmaceutical AB Board effective ...
Continue reading
4 October, 2017

NeuroVive appoints Daniel Schale as Director of Communications

Lund 4 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced the appointment of Daniel Schale as Director of Communicati ...
Continue reading
1 September, 2017

NeuroVive appoints Mark Farmery as Vice President Business Development

Lund, Sweden, September 1, 2017 - NeuroVive Pharmaceutical AB ("NeuroVive" or "the company", Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced the appointment o ...
Continue reading
8 November, 2016
Regulatory

NeuroVive’s recruitment of Michele Tavecchio strengthens its research organization

Lund, Sweden, November 8, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the company has recruited Michele Tavecchio ...
Continue reading
24 August, 2016
Regulatory

NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company

Lund, Sweden, August 24, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its Chief Operating Officer, Jan Nilsson lea ...
Continue reading
11 April, 2016
Regulatory

NeuroVive strengthens its organization with the recruitment of Cecilia Hofvander as IR and Communications Director

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has recruited Cecilia Hofvander as Investor Relations and Communications Director effective from 1 June 2016 i ...
Continue reading
23 February, 2016
Regulatory

Board Selects New CEO Erik Kinnman to Lead NeuroVive

NeuroVive Pharmaceutical AB (publ) board of directors is pleased to announce that it has selected Erik Kinnman as NeuroVive's Chief Executive Officer (CEO). Erik Kinnman will assume the new role on th ...
Continue reading
1 September, 2015
Regulatory

NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces a change in leadership of the company. Effective today, Mikael Brönnegård will no longer serve as Chief Executive Off ...
Continue reading
8 December, 2014
Regulatory

NeuroVive employs a Clinical Trial Manager

NeuroVive Pharmaceutical AB (publ) has recruited Gunilla Lindgren to the position as Clinical Trial Manager. The recruitment enables NeuroVive to ensure the sustained high quality and efficient operat ...
Continue reading
9 October, 2013
Regulatory

Catharina Johansson appointed new CFO, effective 1 December

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has appointed Catharina Johansson as the company's new CFO. She will take up her position on 1 December. This appointment ...
Continue reading

Posts navigation

Older posts
  1. Startpage

This is Abliva

  • Delivering mitochondrial health
  • Orphan Drugs
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • The FALCON Study

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all